A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Assignment Study to Assess the Efficacy and Safety of Reparixin in Pancreatic Islet Auto-Transplantation
Principal Investigator (?)
The study will be a phase 2/3, multicenter, double-blind, parallel assignment study. It will involve 100 adult recipients of an intra-hepatic pancreatic Islet Auto-Transplantation (IAT). The objective of this clinical trial is to assess whether reparixin leads to improved transplant outcome as measured by the proportion of insulin-independent patients following IAT. The safety of reparixin in the specific clinical setting will be also evaluated.
Available at the following location(s)